Skip to Content
Merck
All Photos(2)

Documents

Safety Information

A5602

Sigma-Aldrich

AMD3100 octahydrochloride hydrate

≥97% (NMR), solid, CXCR4 antagonist

Synonym(s):

1,1′-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride, JM3100, Plerixafor, SID791

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C28H54N8 · 8HCl · xH2O
CAS Number:
155148-31-5
Molecular Weight:
794.47 (anhydrous basis)
UNSPSC Code:
51111800
PubChem Substance ID:
24724394
NACRES:
NA.77

product name

AMD3100 octahydrochloride hydrate, ≥97% (NMR), solid

Quality Level

100

Assay

≥97% (NMR)

form

solid

storage condition

desiccated

solubility

H2O: ≥10 mg/mL, clear

originator

Sanofi Aventis

storage temp.

−20°C

SMILES string

Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].[H]O[H].C1CNCCNCCCN(CCNC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2

InChI

1S/C28H54N8.8ClH.H2O/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;;;;;;;;;/h5-8,29-34H,1-4,9-26H2;8*1H;1H2

InChI key

GKFHDCZYJHUPEN-UHFFFAOYSA-N

Application

AMD3100 is a highly specific chemokine receptor CXCR4 antagonist. AMD3100 has been used in a study to determine the blockade of CXCR4 in oral squamous cell carcinoma and inhibition of lymph node metastases.

Biochem/physiol Actions

AMD3100 is a highly specific chemokine receptor CXCR4 antagonist.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

A5602-5MG:
A5602-VAR:
A5602-IP:
A5602-BULK:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

David H McDermott et al.
Blood, 123(15), 2308-2316 (2014-02-14)
Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare immunodeficiency disorder caused by gain-of-function mutations in the G protein-coupled chemokine receptor CXCR4. The CXCR4 antagonist plerixafor, which is approved by the US Food and Drug Administration (FDA) for stem
Brian A Zabel et al.
Molecular cancer, 10, 73-73 (2011-06-16)
Migration of metastatic tumor cells from the bloodstream into lymph nodes is thought to be facilitated by expression of the chemokine receptors CCR7, CXCR4 and, for B cell-derived tumors, CXCR5. Expression of their respective chemokine ligands (CCL19, CCL21, CXCL12 and
Andreas Lundqvist et al.
Journal of immunology (Baltimore, Md. : 1950), 191(12), 6241-6249 (2013-11-19)
Plerixafor (Mozobil) is a CXCR4 antagonist that rapidly mobilizes CD34(+) cells into circulation. Recently, plerixafor has been used as a single agent to mobilize peripheral blood stem cells for allogeneic hematopoietic cell transplantation. Although G-CSF mobilization is known to alter
Sapna Devi et al.
The Journal of experimental medicine, 210(11), 2321-2336 (2013-10-02)
Blood neutrophil homeostasis is essential for successful host defense against invading pathogens. Circulating neutrophil counts are positively regulated by CXCR2 signaling and negatively regulated by the CXCR4-CXCL12 axis. In particular, G-CSF, a known CXCR2 signaler, and plerixafor, a CXCR4 antagonist
Kelli P A MacDonald et al.
Journal of immunology (Baltimore, Md. : 1950), 192(7), 3180-3189 (2014-03-04)
The majority of allogeneic stem cell transplants are currently undertaken using G-CSF mobilized peripheral blood stem cells. G-CSF has diverse biological effects on a broad range of cells and IL-10 is a key regulator of many of these effects. Using
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service